2026-04-29T04:08:44Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/236312024-11-29T00:48:47Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Zamanillo Campos, Rocío
author
Fiol-deRoque, Maria Antonia
author
Serrano-Ripoll, Maria Jesus
author
Mira-Martínez, Sofía
author
Llobera Cànaves, Joan
author
Taltavull Aparicio, Joana Maria
author
Leiva, Alfonso
author
Ripoll Amengual, Joana
author
Angullo Martinez, Escarlata
author
Socias Buades, Isabel Maria
author
Masmiquel, Lluis
author
Konieczna, Jadwiga
author
Zaforteza Dezcallar, María
author
Boronat-Moreiro, Maria Asunción
author
Gervilla Garcia, Elena
author
Ricci-Cabello, Ignacio
2024-10-09T06:33:53Z
2024-10-09T06:33:53Z
2023-11-22
Zamanillo-Campos R, Fiol-DeRoque MA, Serrano-Ripoll MJ, Mira-Martínez S, Llobera-Canaves J, Taltavull-Aparicio JM, et al. DiabeText, a mobile health intervention to support medication taking and healthy lifestyle in adults with type 2 diabetes: Study protocol for a randomized controlled trial. Contemp Clin Trials. 2024 Jan;136:107399.
https://hdl.handle.net/20.500.13003/20115
https://hdl.handle.net/20.500.12105/23631
37995967
10.1016/j.cct.2023.107399
1559-2030
Contemporary clinical trials
2-s2.0-85181718678
1127807300001
L2028676152
Aim: To evaluate the effectiveness of DiabeText, a low-intensity, multifaceted, mobile health (mHealth) intervention to support medication taking and lifestyle change targeted to people with type 2 diabetes (T2D). Design: Phase III, 12-months, two-arm (1:1 allocation ratio), randomized parallel-group trial. Methods: We will recruit 740 adults with glycated hemoglobin (A1c) >8% (>64 mmol/mol) and with at least one prescription of a non-insulin antidiabetic drug. They will be allocated to a control (usual care) group or an intervention (DiabeText messaging intervention) group. The primary outcome measure will be A1c at 12 months follow-up. Secondary outcomes will include medication possession ratio and behavioral and psychological outcomes. Discussion: Recent trials suggest that digital health interventions can effectively support diabetes self-management improving T2D control and reducing important T2D complications. In Spain this type of interventions is understudied. Impact: This trial will strengthen the evidence base of the impact of mHealth interventions to support diabetes self-management. If effective, DiabeText may offer a low-cost and highly scalable strategy to improve health at the population level in a sustainable way. Trial registration: ClinicalTrials.gov identifier NCT05006872; Official Title: Supporting People with Type 2 Diabetes in Effective Use of their Medicine Through a System Comprising Mobile Health Technology Integrated with Clinical Care.
eng
DiabeText, a mobile health intervention to support medication taking and healthy lifestyle in adults with type 2 diabetes: Study protocol for a randomized controlled trial
research article